Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Now, scientists in Korea have discovered that the Parkinson’s disease drug procyclidine can alleviate physical symptoms of ...

In December 2003, Osbourne was involved in an accident while riding his four-wheel all-terrain vehicle at his English estate.

Dr. Heh-In Im at the Center for Brain Disorders of the Korea Institute of Science and Technology (KIST) has identified a novel brain region and neural mechanism involved in regulating nicotine ...

A new study from the University of East Anglia has found that long-term use of certain antidepressants may increase the risk of dementia, even if taken up to 20 years before a diagnosis. The study ...

The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) injection, the first and only ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit.A new study ...